Biotech

All Articles

Actinogen's cortisol blocker falls short period 2 depression research

.Actinogen Medical's cortisol blocker has actually missed the main endpoint of a period 2 study in c...

Bivictrix makes a decision going private only technique to take ADC in to center

.Antibody-drug conjugates (ADCs) have actually been at the center of numerous a billion-dollar biobu...

TPG leadings up funds to $580M for expenditures around life sciences

.Asset supervisor TPG, which has supported biotechs such as Sionna Rehabs as well as Santa Clam Ana ...

Merck stops stage 3 TIGIT test in bronchi cancer cells for impossibility

.Merck &amp Co.'s TIGIT course has actually suffered another setback. Months after shuttering a peri...

After a tough year, Exscientia folds into Recursion

.After a year specified through pipe hairstyles, the departure of its own CEO as well as cutbacks, E...

Cullinan, after $25M deal, return bispecific to Port

.Cullinan Therapy was wowed enough with Port BioMed's bispecific immune system activator that it gav...

A closer examine Intense Biotech's Intense 15

.In this particular full week's incident of "The Best Pipe," our company are actually diving into In...

Lilly deals with stage 2 breakdown of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's event celebrating the commendation o...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of significant management hirings, firings ...

Lykos will certainly inquire FDA to reexamine its selection complying with denial of MDMA therapy for trauma

.Observing a poor showing for Lykos Rehabs' MDMA applicant for post-traumatic stress disorder at a l...